Brazil · Delayed Price · Currency is BRL Fleury Earnings Call Transcripts
Fiscal Year 2025
-
Delivered strong revenue and EBITDA growth in 2025, driven by B2C, B2B, and New Links expansion, disciplined cost management, and strategic acquisitions. Maintained stable margins, robust cash generation, and increased ROIC, with continued focus on digital transformation and operational efficiency.
-
Q3 2025 saw 11.5% revenue growth, strong B2C and mobile care expansion, and stable margins. Strategic acquisitions in São Paulo and Campinas enhanced market presence, while robust cash flow and disciplined capital allocation supported high dividends and future growth.
-
Q2 2025 saw modest revenue growth and stable EBITDA, but net income declined due to calendar effects and contract terminations. Investments in digitalization and recent acquisitions support future growth, with a strong cash position and disciplined capital allocation.
-
Q1 2025 saw 6.5% revenue growth, strong B2C and regional brand performance, and robust digital adoption, with EBITDA and net profit up 5.9% and 6.7% respectively. ROIC improved to 16.9%, leverage remained low, and high payout was maintained.
Fiscal Year 2024
-
Strong revenue and net income growth in 2024, driven by successful integration, digital innovation, and strategic acquisitions. Margins expanded, cash generation was robust, and the company remains well-positioned for continued market share gains and operational efficiency.
-
Q3 2024 saw 6.1% revenue growth to BRL 2.1B, with EBITDA up 6.2% and net profit up 9.5%. Integration with Pardini and expansion in B2B, mobile, and new health platforms drove results, while cost discipline and digital initiatives supported margins.
-
Q2 2024 saw 19.7% revenue growth and 47.5% higher net income, driven by the Pardini integration, B2B expansion, and cost discipline. Synergy capture is on track, leverage remains low, and the group continues to diversify revenue and invest in digital initiatives.